Prevention of sarcopenia by biologic agents and JAK inhibitors in rheumatoid arthritis; PRESENT study

Prevention of sarcopenia by biologic agents and JAK inhibitors in rheumatoid arthritis; PRESENT study - PRESENT study

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000037797

Enrollment

200

Registered

2019-08-30

Start date

2019-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis, Sarcopenia

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Rheumatoid arthritis patients fulfilled ACR/EULAR 2010 classification 2.Uncontrolled disease patients using conventional DMARDs over 12 weeks. Uncontrolled disease was defined below 3 conditions. .Swelling joint count over 6 .Tender joint count over 6 .CRP over 2.0mg/dl or ESR over 28mm/hr If the patients do not fulfilled, .Progressive bone erosion on X-ray .DAS28-ESR over 3.2 3.Included all disease duration

Exclusion criteria

Exclusion criteria: 1.Complicated with sever complication patients 2.Autoimmune disease patients effected inflammation except rheumatoid arthritis

Design outcomes

Primary

Measure	Time frame
Incidence rate of sarcopenia at 52 weeks	—

Countries

Japan

Contacts

Public ContactMashiro Tada

Osaka City General Hospital Orthopaedic surgery

m-tada@med.osaka-cu.ac.jp06-6929-1221

Outcome results